Skip to main content
ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SPRY ISIN · US82835W1080 US Manufacturing
Filings indexed 491 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country US United States of America
Listing US SPRY

About ARS Pharmaceuticals, Inc.

https://ars-pharma.com/

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative, needle-free products for administering therapies. The company's lead product is neffy (epinephrine nasal spray), the first and only FDA-approved needle-free treatment for severe allergic reactions (Type I hypersensitivity), including anaphylaxis. Developed as a patient-friendly alternative to auto-injectors, neffy is designed to be easy to carry and use, addressing challenges such as needle-related risks and hesitation in administration for both patients and caregivers.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report
2026-05-15 English
8-K
Regulatory Filings
2026-05-15 English
8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
Regulatory Filings
2026-05-13 English
Director's Dealing 2026
Director's Dealing
2026-01-05 English
Director's Dealing 2026
Director's Dealing
2026-01-05 English
Director's Dealing 2026
Director's Dealing
2026-01-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.